Week 8 Coagulation Lecture 5&6 - Thrombotic Disorders Flashcards
Venous Thrombosis
Most commonly occurs in the legs
Thrombophlebitis
- thrombosis in the superficial veins
- inflammation or stasis
- self-resolving
Deep vein thrombosis
- most common site is in the deep veins of the legs
- pulmonary embolism is a serious complication
Thrombi commonly form around the valves of the leg veins
VT initiates after endothelial cell activation → fibrin formation at the endothelial surface
Fibrin traps RBCs and platelets
Venous Thrombosis - Pathogenesis
Mechanisms of endothelial activation
- inflammation
- stasis at the back of the valve → hypoxia → EC activation
Activated ECs
- express TF
- express P-selectin (allows leukocytes to bind to the endothelium)
- release vWF (allows platelets and leukocytes to bind to the endothelium)
Stasis
- accumulation of prothrombotic factors
- hypoxia in leukocytes, platelets, (and ECs) => expression of TF in monocytes and production of TF-bearing microparticles
- anticoagulant function of the endothelium is decreased in large vessels
Diagnosis of Venous Thrombosis
Symptomatic patient
Presence of risk factors
D-dimer
- elevated in VTE
- not diagnostic, but can be used to exclude VTE
Imaging
Treatment of Deep Vein Thrombosis
Initially, heparin
- usually LMWH
- UFH only in certain patient populations
Then warfarin or other orally administered anticoagulant
- continues for 3-6 months, to years
Risk Factors for Venous Thrombosis
Hospitalisation
Lupus anticoagulant
Cancer
Trauma/fracture
Pregnancy
Oral contraceptives/oestrogen
Obesity
Hereditary Thrombophilia
Reduced levels of the naturally occurring anticoagulants:
- antithrombin (AT)
- protein C (PC)
- protein S (PS)
AT and PC have type I and type II deficiencies
- type I: decreased antigenic levels of functional protein
- type II: normal antigenic levels of protein with decreased function
Factor V Leiden (FVL)
Prothrombin Gene Mutation
Antithrombin
AT inhibits serine proteases
Main targets are IIa (thrombin), IXa, Xa, XIa, XIIa
Activity is greatly enhanced by heparin/heparan sulphate
Contains two major functional regions
- reactive site
- heparin/heparan binding
Antithrombin Testing
Both functional and antigenic assays used for the measurement of AT
Functional - heparin co-factor assay
- patient plasma is mixed with heparin and thrombin
- residual thrombin activity is determined with the addition of a thrombin-specific chromogenic substrate
Antigenic - ELISA, latex-agglutination
Congenital AT Deficiency
Affected individuals experience their first thrombotic episode in the first 25 years of life
Heterozygous deficiency confers a 10-20 fold increased thrombotic risk
Homozygous deficiency is incompatible with life
- except for mutations in the heparin-binding site
The Protein C/Protein S System
Contains Protein C (PC), Protein S (PS), Thrombomodulin (TM), and the Endothelial Protein C Receptor (EPCR)
PC and PS are vitamin-K dependent proteins produced by the liver
TM is expressed on the EC surface
- binds “non-clot bound” thrombin
- changes thrombin’s substrate specificity
EPCR is expressed on the endothelial surface, binds PC
Protein C - Activity Assays
Should be used to measure PC
Chromogenic or clot-based (aPTT)
Both use Protac, which activates Protein C
In the clot-based assay, normal plasma has a prolonged time (< 100s), whereas PC ↓ plasma has a normal time (30-40s)
Chromogenic assays do not detect PC that has abnormal PL or Ca2+ binding, but are preferred over clot-based assays
Clot-based assays may underestimate PC activity in the presence of FVL, ↑ FVIII, hyperlipidaemia, and may give unreliable results in the presence of lupus anticoagulants
Protein S
Two pools of PS are present in plasma
- ~60% is bound to C4bp (no co-factor function)
- ~40% circulates unbound
Free vs total PS
Assays:
- total PS antigenic assay
- free PS antigenic assay
- PS functional (activity) assay
- low levels found in the functional assay should be confirmed with free PS antigenic assay
Protein S - 3 Types of Deficiency
Type I
- normal PS protein is produced at a reduced level
- decreased antigenic and functional PS
Type II
- normal levels of PS with decreased functional activity
- normal antigenic levels, decreased functional levels
Type III
- decreased free PS antigen, normal total PS antigen
The Prothrombin Gene Mutation
A.k.a the Prothrombin G20210A mutation
Mutation in the 3’ UTR of the F2 gene
Increases the stability of the F2 mRNA
Heterozygotes have elevated plasma Prothrombin relative to homozygous WT (~30% increase)
Elevated Prothrombin → increased thrombin generation
Can only be identified by molecular testing
Factor V Leiden
The most common thrombophilia
Occurs almost exclusively in Caucasians
Heterozygosity increases thrombotic risk by ~ 2-fold
Homozygosity increases thrombotic risk by ~10-fold
A mutation in F5 results in an arginine to glutamine change at position 506 of the fV protein
In FVL, aPC doesn’t recognise the Gln at position 506, so it doesn’t cleave at position 506
Therefore, in the absence of Protein S, activated FVL is inactivated by aPC at a much slower rate than fVa